The Best Stocks to Invest $40 in to Start the New Year Off Right

Pfizer (trading around $26) is being pitched as a buy based on a deep pipeline highlighted by late-stage oncology candidate PF-4404 and a promising weight-management asset MET-097i acquired last year, alongside a three-year White House deal exempting certain imports from duties in exchange for reduced U.S. prices that helps blunt upcoming patent-cliff risks. Viking Therapeutics (around $34) is described as higher-risk/higher-reward: its leading weight-loss candidate VK2735 is in phase 3 as a subcutaneous formulation with a mid-stage oral program and maintenance studies designed to address post-treatment weight regain. Both names have underperformed but the article argues clinical progress or approvals over the next 1–3 years could materially re-rate their shares, while noting Viking’s greater clinical and regulatory risk.

Analysis

Market structure: Positive for Pfizer (PFE) if PF-4404 and MET-097i convert to approvals — these assets can partially offset patent cliffs and the White House tariff deal eases near-term gross-margin pressure for three years. Viking (VKTX) is a potential disruptor in obesity/weight-management markets dominated by Novo Nordisk (NVO) and Eli Lilly (LLY); success of VK2735 (subcutaneous + oral maintenance) would expand addressable market but likely compress prices vs today’s premium GLP‑1 pricing. Cross-asset: a successful set of readouts would tighten credit spreads for large pharma, lift biotech equity vols on trial timelines, and could modestly strengthen USD on increased pharma M&A flows; failed readouts would push flows into Treasuries and widen IG/biotech spreads.

Risk assessment: Tail risks include Phase‑3 failure or safety signal (VKTX/PFE), adverse FDA guidance, and policy risk if the tariff/price concessions become a template for broader U.S. price controls after three years. Time horizons: immediate (days–weeks) = elevated IV and headline-driven moves; short (3–12 months) = pivotal trial readouts and dosing/regulatory updates; long (2–5 years) = revenue ramp, reimbursement decisions, and potential M&A. Hidden dependencies: reimbursement decisions, manufacturing scale-up (subcutaneous vs oral), and the three‑year tariff carve‑out expiry could reintroduce margin pressure. Key catalysts: Phase‑3 readouts for VK2735 (6–18 months) and PF‑4404 late‑stage data (12–36 months); any M&A chatter would accelerate re-rating.

Trade implications: Direct: tilt into PFE at current ~$26 as a core pharma recovery trade sized 2–3% of portfolio with a 12–36 month horizon; keep VKTX as a 1% speculative sleeve sized for binary risk pending Phase‑3 readouts. Options: prefer defined‑risk structures — buy-call spreads on VKTX around key data windows or sell out‑of‑the‑money puts for PFE to collect premium while acquiring exposure; size to max portfolio downside of 1–2% per trade. Sector rotation: overweight diversified large pharma and selective biotech R&D exposure, underweight pure GLP‑1 premium plays if U.S. pricing reform risks accelerate post‑tariff expiration.

Contrarian angles: Consensus underprices Pfizer’s pipeline optionality and overprices the inevitability of GLP‑1 pricing power — if VK2735 proves effective with oral maintenance, adoption could expand the market and force incumbents into price competition, meaning disruption rather than pure cannibalization. Market may be under-reacting to the three‑year tariff window — use that horizon (36 months) as a clock: take small, time‑staggered positions and re‑assess around policy expiration. Historical parallels: biotech binary rallies (e.g., GLP‑1 era) saw acquirers swoop in post‑positive readouts — therefore M&A upside exists and justifies measured long exposure despite high trial risk.

Key Decisions for Investors

• Establish a 2–3% long position in Pfizer (PFE) at or below current levels (~$26), target a 12–36 month hold for pipeline re‑rating; add to position if price falls below $22 or after a positive PF‑4404 or MET‑097i readout. Hedge by buying a 12‑month $20 put (~protects downside below ~20) sized to cap portfolio loss to ~1% if worst case.
• Take a speculative 1% position in Viking Therapeutics (VKTX) via defined‑risk long call spreads expiring 9–18 months around expected Phase‑3 readouts (buy ATM, sell OTM) to limit downside; use a 50% stop loss on outright equity exposure and cap eventual total exposure at 2% if consecutive positive data emerge.
• Execute a pair trade: go long PFE (2%) and short 1% of Eli Lilly (LLY) or Novo Nordisk (NVO) for 6–12 months to express a view that price concessions and competitive entrants will compress GLP‑1 pure‑play margins faster than diversified pharma earnings. Close or rebalance within 90 days of any major pricing/policy announcement or at tariff carve‑out end (36 months).
• Monitor three specific catalysts over the next 6–18 months (VK2735 Phase‑3 interim/final data, PF‑4404 trial milestones, and any federal pricing policy extending beyond the 3‑year tariff deal). If two of three catalysts confirm upside, increase biotech exposure by +1–2% and tighten stop losses; if negative, trim positions by 50% within 30 days.